EGRX
vs
S&P 500
EGRX
S&P 500
Over the past 12 months, EGRX has underperformed S&P 500, delivering a return of -84% compared to the S&P 500's +18% growth.
Stocks Performance
EGRX vs S&P 500
Performance Gap
EGRX vs S&P 500
Performance By Year
EGRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Eagle Pharmaceuticals Inc
Glance View
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 102 full-time employees. The company went IPO on 2014-02-12. The firm's commercialized products include Ryanodex, Bendeka, Belrapzo, Treakisym, and Pemfexy. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, Bendeka and Treakisym are used for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Pemfexy is an IV-administered cancer agent indicated for locally advanced or metastatic non-small cell lung cancer and mesothelioma. Its oncology and CNS/metabolic critical care pipeline includes product candidates that addresses underserved therapeutic areas across multiple disease states. Its vasopressin is an A-rated generic alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The company is engaged in clinical trials for CAL02, an approach to the treatment of severe bacterial pneumonia.
